Dyadic International said today it will sell its industrial technology business to DuPont’s Industrial Biosciences business for $75 million cash, in a deal that will reposition the seller exclusively ...
Dyadic International's fair value estimate has held steady at $5.67 per share, even as the discount rate has risen slightly from 7.04% to 7.20%. This adjustment reflects a blend of optimism about ...
JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today ...
Hosted on MSN
Dyadic outlines new commercial focus as first bulk protein sales and Asia expansion accelerate growth trajectory
Hazelton confirmed Dyadic expects momentum to build with additional product opportunities in 2025, accelerating in 2026 as the company scales its portfolio and expands its global market reach. He ...
JUPITER, Fla., May 7, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme ...
On December 23, 2025, Dyadic International, Inc. amended its Senior Secured Convertible Promissory Notes due March 8, 2027, extending their maturity date to December 31, 2027, changing the conversion ...
Dyadic International, Inc. has announced a leadership change, appointing Joe Hazelton as President to enhance its strategy of focusing on ancillary recombinant protein products for life sciences, ...
Dyadic International, Inc., a biotechnology firm specializing in large-scale protein production for vaccines and therapeutics, provided an update on its business development efforts, particularly in ...
Infants' abilities to focus attention on objects are known to be related to mothers' mobilizing behaviors. As delayed effects of maternal behaviors at 5 months may be observed in 8-month-olds, mothers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback